CSL Behring’s therapy for hereditary angioedema receives positive assessment in Germany
June 26, 2025Market Access, Market Research, Medical Communications, Research and Development, Sales and Marketing CSL Behring, Institute for Quality and Efficiency in Health Care, Rare Diseases, clinical trials, hereditary angioedema, market access
CSL Behring has announced a key milestone for its hereditary angioedema (HAE) therapy, garadacimab, following a positive benefit assessment by …
FDA grants orphan drug designation to antibody-mediated rejection treatment
June 26, 2025Research and Development FDA, Immunology, Orphan Drug Designation, Sanofi, antibody-mediated rejection, clinical trials, immunology, inflammation, organ transplantation
Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to riliprubart for …
Oxeltis secures €800,000 grant to advance antiviral candidate for emerging tropical viruses
June 26, 2025Medical Communications, Research and Development Corporate, Defense Innovation Agency, National Research Agency, Oxeltis, RNA viruses, Virology, contract research organisation
Oxeltis, a French contract research organisation specialising in medicinal and organic chemistry, has announced that it will lead the BUNYANTIVIR …
Roche candidate shows early promise for treating haemophilia A
June 25, 2025Research and Development Chugai, Haematology, Roche, clinical trial, haemophilia a, prophylactic therapy
Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational bispecific antibody for haemophilia A. …
Novo Nordisk’s therapy delivers significant weight loss in trial
June 25, 2025Research and Development Novo Nordisk, Obesity, obesity, weight loss, weight-related medical conditions
Novo Nordisk has announced promising results from its phase 3 REDEFINE 1 trial, showing that investigational weight loss therapy, CagriSema, …
Opterion Health strengthens board with appointments of Rice Powell and Mark Hahn
June 25, 2025Research and Development CEO, Nephrology, Opterion Health, board of directors, cfo, chronic kidney disease, dialysis solution
Swiss life sciences company Opterion Health has appointed two senior industry figures to its board of directors: Rice Powell, former …
PLL Therapeutics appoints renowned ALS expert Philippe Corcia to scientific board
June 25, 2025Research and Development ALS Reference Centre, National ALS Motor Neuron Study Group, Neurology, PLL Therapeutics, amyotrophic lateral sclerosis (ALS), scientific board
PLL Therapeutics has appointed leading amyotrophic lateral sclerosis (ALS) researcher Philippe Corcia to its scientific board, marking a strategic move …
NHS ConfedExpo 2025: a platform for change in UK health and care
June 24, 2025Medical Communications Accenture, AstraZeneca, Corporate, Excellence in healthcare Partnership (EHP) Awards, Manchester, NHS ConfedExpo, NHS Confederation, NHS England, Novartis UK, Visions4Health
This year’s NHS ConfedExpo took place on 11 to 12 June at Manchester Central, bringing together around 9,000 attendees. Among …
Sarclisa recommended for EU approval in newly diagnosed multiple myeloma
June 24, 2025Research and Development Committee for Medicinal Products for Human USE, EU, European Commission, European Medicines Agency, German-speaking Myeloma Multicenter Group, Oncology, Sanofi, blood cancer, monoclonal antibody
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi’s Sarclisa (isatuximab) for approval in …
Neurizon confirms positive results for prospective ALS treatment
June 23, 2025Research and Development Neurizon Therapeutics, Neurology, amyotrophic lateral sclerosis, blood-brain barrier, clinical data, neurodegenerative diseases
Neurizon Therapeutics has announced new preclinical data confirming that NUZ-001 and its active metabolite, NUZ-001 Sulfone, effectively cross the blood-brain …
AOTI achieves broad market access in Germany for diabetic foot ulcer therapy
June 23, 2025Market Access, Medical Communications, Sales and Marketing AOTI, Diabetes, European pharma market, German pharma market, Wound Healing, diabetic foot ulcers, market access, positive recommendation
AOTI, focused on solutions for severe and chronic wounds, has announced that its unique topical wound oxygen (TWO2) therapy has …
Novo Nordisk presents promising findings for haemophilia treatment
June 23, 2025Medical Communications, Research and Development Haematology, International Society on Thrombosis and Haemostasis Congres, Novo Nordisk, clinical trial data, haemophilia, market approval
Novo Nordisk has presented data indicating that a direct switch to Mim8 (denecimig) prophylaxis treatment from emicizumab without a need …
Terumo BCT showcases new CAR-T workflow enabling faster cell expansion
June 20, 2025Manufacturing and Production CAR-T cell manufacturing, Devices, EULV, Eureka Biotechnology, Terumo Blood and Cell Technologies, cell therapy, eureka, gene therapy
Terumo Blood and Cell Technologies (Terumo BCT) has unveiled a new automated workflow that consolidates three critical CAR-T manufacturing steps …
NICE recommends spevigo for rare and severe psoriasis flares
June 20, 2025Medical Communications, Research and Development Dermatology, NHS, National Institute for Health and Care Excellence, generalised pustular psoriasis
The National Institute for Health and Care Excellence (NICE) has recommended Spevigo (spesolimab) for the treatment of generalised pustular psoriasis …
First UK patient treated with CSL Behring’s gene therapy for Haemophilia B
June 20, 2025Research and Development CSL Behring, Haematology, NHS England, cell therapy, gene therapy, haemophilia B, prophylactic infusions
CSL Behring has announced that the first patient in the UK has received HEMGENIX (etranacogene dezaparvovec) through the NHS, marking …
Eyestem completes phase 1 trial of retinal cell therapy with promising vision gains
June 20, 2025Research and Development Eyestem Research, Opthalmology, cell therapy, clinical trial, dry age-related macular degeneration, geographic atrophy
Eyestem Research has announced the successful completion of its phase 1 trial evaluating Eyecyte-RPE, an investigational cell therapy for geographic …
Nanoform receives €5m loan from Finnish government to accelerate its nanotechnology
June 20, 2025Freelancers, Licensing & business development, Research and Development Devices, Johnson & Johnson, Nanoform Finland, Oncology, amorphous solid dispersion technology, government loan, nanoparticle medicine, nanotechnology, prostate cancer
Nanoform Finland [Nanoform], a leading nanoparticle medicine company, is pleased to announce that Business Finland has approved a €5m research …
Celltrion opens new UK headquarters in Uxbridge to drive long-term growth
June 19, 2025Research and Development Corporate, Pharmacy, biosimilar medicines, celltrion
Celltrion, focused on the development of biosimilar medicines, has officially opened its new UK headquarters in the Charter Building, Uxbridge, …
KFSHRC and Germfree to launch first modular ATMP manufacturing campus in Saudi Arabia
June 19, 2025Medical Communications, Research and Development Advanced Therapy Medicinal Product manufacturing, BIO 2025, Corporate, King Faisal Specialist Hospital & Research Centre, Saudi Arabia, biotechnology development, cell therapies, gene therapies
King Faisal Specialist Hospital & Research Centre (KFSHRC) has announced a landmark partnership with Germfree Laboratories to develop Saudi Arabia’s …
Alan Perkins awarded MBE for services to patient care and clinical science
June 19, 2025Medical Communications Devices, MBE, Serac Life Sciences, medical imaging technology, molecular imaging, nuclear medicine, scientific advisor
Serac Life Sciences has announced that Alan Perkins, scientific advisor to its subsidiaries Serac Healthcare and Serac Imaging Systems, has …
